Capsule Summary Slidesets

Share

Program Content

Activities

  • HER2CLIMB: Tucatinib in HER2+ MBC
    HER2CLIMB: Phase II Study of Tucatinib Plus Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2019

    Expires: December 14, 2020

  • SOPHIA 2nd Interim OS Analysis
    SOPHIA: Second Interim OS Analysis of Margetuximab + CT vs Trastuzumab + CT for HER2+ MBC After Previous HER2 Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2019

    Expires: December 18, 2020

  • DESTINY-Breast01
    DESTINY-Breast01: Phase II Study of Trastuzumab Deruxtecan (DS-8201a) in HER2+ Advanced Breast Cancer Previously Treated With T-DM1
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2019

    Expires: December 16, 2020

  • APHINITY: CT + Trastuzumab/Pertuzumab Updated OS
    APHINITY: Interim OS Analysis of Adjuvant CT Plus Trastuzumab With vs Without Pertuzumab for Patients With HER2+ EBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2019

    Expires: December 14, 2020

  • ATEMPT: T-DM1 vs TH in Stage I EBC
    Phase II ATEMPT: Analysis of Adjuvant Trastuzumab Emtansine (T-DM1) vs Paclitaxel Plus Trastuzumab in Patients With Stage I HER2-Positive Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2019

    Expires: December 17, 2020

  • PEARL: Palbociclib + ET vs CAPE in HR+ MBC
    PEARL: Palbociclib + Endocrine Therapy vs Capecitabine in Postmenopausal Women With HR+/HER- MBC and Previous AI Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2019

    Expires: December 18, 2020

  • KEYNOTE-522: pCR by Subgroups
    KEYNOTE-522 Study of Neoadjuvant Pembrolizumab vs Placebo in Combination With Chemotherapy for Early-Stage TNBC: Subgroup Analysis of pCR
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2019

    Expires: December 17, 2020

  • plasmaMATCH: ctDNA to Direct Tx in Adv BC
    plasmaMATCH (CRUK/15/010): Evaluation of Circulating Tumor DNA Testing to Direct Targeted Therapies in Patients with Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2019

    Expires: December 18, 2020

  • NSABP B-42 10-Yr Follow-up
    NSABP B-42 10-Yr Follow-up: Extended Adjuvant Letrozole After Previous Adjuvant AI Therapy in Postmenopausal Women With HR+ Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2019

    Expires: December 17, 2020

  • Oral vs IV Paclitaxel in MBC
    Oral Paclitaxel With P-Glycoprotein Pump Inhibitor Encequidar vs Intravenous Paclitaxel in Metastatic Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2019

    Expires: December 18, 2020

  • INFORM Neoadjuvant Trial
    INFORM: Randomized Phase II Study of Neoadjuvant Cisplatin vs AC in Newly Diagnosed Breast Cancer With Germline BRCA Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2019

    Expires: December 15, 2020

  • T-DXd and QTc/PK in MBC
    Phase I Study to Assess the Effect of Trastuzumab Deruxtecan on QTc Interval and Pharmacokinetics in HER2-Expressing Metastatic or Unresectable Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2019

    Expires: December 18, 2020

  • Neratinib for <i>HER2</i>-mutant ABC
    plasmaMATCH Cohort B: Neratinib ± Fulvestrant for Patients With HER2 Mutation–Positive Advanced Breast Cancer as Identified by ctDNA Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2019

    Expires: December 15, 2020

  • Neratinib in HER2+ MBC
    Impact of Neratinib on CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer: Analysis of Data From Phase II/III Trials
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2019

    Expires: December 18, 2020

  • CONTROL: Neratinib-Associated Diarrhea
    CONTROL: Phase II Trial of Antidiarrheal Prophylaxis or Neratinib Dose Escalation for Neratinib-Associated Diarrhea in Patients With HER2+ Early BC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2019

    Expires: December 14, 2020

  • Neoadj CT ± Atezo in TNBC
    NeoTRIPaPDL1 Michelangelo: Neoadjuvant Chemotherapy ± Atezolizumab in Early, High-Risk and Locally Advanced TNBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen